Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Overcoming technological and biological barriers to pulmonary mRNA delivery with lipid-polymer hybrid nanoparticles.

Created on 31 Oct 2026

Authors

Achim Biesel, Aparna Shandheep, Andreas Pavlou, Lena Mareike Busker, Marcus Koch, Vesa Kopliku, Katharina Maisel, Annette Boese, Jennifer Skerra, Lara-Jasmin Schröder, Lavinia Neubert, Nicole Schneider-Daum, Brigitta Loretz, Ulrich Kalinke, Claus-Michael Lehr

Published in

Journal of controlled release : official journal of the Controlled Release Society. Pages 115509. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

Delivering mRNA to the lungs promises treatment of genetic, infectious and non-communicable lung diseases. Yet, conventional lipid nanoparticle formulations lack the stability needed to endure the harsh mechanical stress during nebulization. Additionally, once deposited in the respiratory tract, gene delivery systems may first have to overcome the mucus barrier, before actually transfecting the target cells. To overcome these challenges, we utilize lipid-polymer hybrid nanoparticles (LPH), merging the stability of pharmaceutical polymers with the transfection efficiency of cationic and ionizable lipids. LPH are produced in a robust microfluidic process, accomplish near-complete encapsulation efficiency, even after nebulization, and confer high transfection efficiency in A549 cells. To provide colloidal stability after aerosolization, we developed a coating strategy with hyaluronic acid (HA) and poly(vinyl alcohol) (PVA), ensuring ideal nebulization stability by steric shielding. This formulation showed good transfection efficiency of air-liquid interface grown Calu-3 cells, producing and covered by mucus. The potential of LPH to deliver mRNA to mammalian cells was first shown in primary human lung fibroblasts in vitro and could also be confirmed after intratracheal administration to mice in vivo. Together, these findings validate LPH as a versatile and aerosolizable mRNA delivery platform, overcoming the key technological and biological barriers in pulmonary gene delivery.

PMID:
42962826
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 63
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement